| Trade Names: | |
| Synonyms: | |
| Status: | Approved (2009) |
| Entry Type: | Small molecule |
| Molecule Category: | Salt Prodrug |
| UNII: | BEA68ZVB2K |
| Parent Compound: | ESLICARBAZEPINE |
Structure
| InChI Key | QIALRBLEEWJACW-INIZCTEOSA-N |
|---|---|
| Smile | |
| InChI |
|
Physicochemical Descriptors
| Property Name | Value |
|---|---|
| Molecular Formula | C17H16N2O3 |
| Molecular Weight | 296.33 |
| AlogP | 3.06 |
| Hydrogen Bond Acceptor | 3.0 |
| Hydrogen Bond Donor | 1.0 |
| Number of Rotational Bond | 1.0 |
| Polar Surface Area | 72.63 |
| Molecular species | NEUTRAL |
| Aromatic Rings | 2.0 |
| Heavy Atoms | 22.0 |
Pharmacology
| Targets | EC50(nM) | IC50(nM) | Kd(nM) | Ki(nM) | Inhibition(%) | |
|---|---|---|---|---|---|---|
|
Ion channel
Ligand-gated ion channel
P2X receptor
|
- | - | - | - | 25 |
Indications
| Mesh Heading | Maximum Phase | Mesh ID | Reference |
|---|---|---|---|
| Epilepsy, Complex Partial | 3 | D017029 | ClinicalTrials |
| Diabetic Neuropathies | 3 | D003929 | ClinicalTrials |
| Neuralgia, Postherpetic | 3 | D051474 | ClinicalTrials |
| Epilepsies, Partial | 3 | D004828 | ClinicalTrials |
| Migraine Disorders | 2 | D008881 | ClinicalTrials |
| Bipolar Disorder | 2 | D001714 | ClinicalTrials |
| Fibromyalgia | 2 | D005356 | ClinicalTrials |
| Neuralgia | 1 | D009437 | ClinicalTrials |
Related Entries
Scaffolds
Adverse Reactions
System Organ Classification (SOC)
Cross References
| Resources | Reference |
|---|---|
| CAS NUMBER | 236395-14-5 |
| ChEBI | 87016 |
| ChEMBL | CHEMBL87992 |
| DrugBank | DB09119 |
| DrugCentral | 4303 |
| EPA CompTox | DTXSID90178308 |
| FDA SRS | BEA68ZVB2K |
| PubChem | 179344 |
| SureChEMBL | SCHEMBL250594 |
| ZINC | ZINC000000007295 |
CONTENTS